Thus, repurposing inhibitors targeting ABL1/2 and DDR1, many of which are FDA-approved, may be an effective therapeutic approach, in combination with MEKi, for patients with metastatic NRAS-mutant melanomas that fail to respond to immune-checkpoint blockade and thus, have no effective second-line treatment options. This evidence concerns the gene DDR1 and melanoma.